A randomized, double-blind phase II/III study (NCT05785767) is investigating fianlimab (αLAG-3) combined with cemiplimab (αPD-1) as first- line therapy for advanced NSCLC with PD-L1≥50%, including patients previously treated with PD-1/L1 or CTLA-4 inhibitors. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.